SCHEMBL4499303

SCHEMBL4499303

CC(=O)N1CCN(c2ccc(NC(=O)c3nnc(NC(=O)Cc4cccs4)o3)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.60
MAPT P10636 8/20 0.56
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 2/20 0.56
GAA P10253 1/20 0.56
ALOX15 P16050 1/20 0.56
ALOX12 P18054 1/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
POLB P06746 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CYP2C19 P33261 1/20 0.48
GFER P55789 1/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504703 0.86 DGAT1 (0.63) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL4508156 0.85 DGAT1 (0.57) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL4501137 0.83 DGAT1 (0.57) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL4504162 0.80 DGAT1 (0.57) DGAT1MAPTALDH1A1NPC1RAB9A
SCHEMBL3547530 0.79 DGAT1 (0.77) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL4510365 0.78 DGAT1 (0.65) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL4518459 0.78 MAPT (0.74) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL27731982 0.78 MAPT (0.57) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL4517504 0.78 DGAT1 (0.64) DGAT1MAPTALDH1A1MEN1KMT2A
SCHEMBL3545843 0.77 DGAT1 (0.71) DGAT1MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885MAPT 2561/4885ALDH1A1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.